Newron Pharmaceuticals S.p.A. (NP5.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR

Add to watchlist

9.45

-0.14

(-1.46%)

At close: 08:07AM CEST

Loading interactive chart...

Business Wire
Newron Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients
MILAN, May 13, 2024--Newron reports new data from pivotal study 008A for chronic schizophrenia patients revealing clinically significant efficacy benefits over time.
Business Wire
Newron Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients
MILAN, April 30, 2024--Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
Business Wire
Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
MILAN, April 08, 2024--Newron presents existing evenamide study 014/015 data and future clinical development outlook for evenamide at 2024 SIRS Congress in Florence, Italy